Sugi Predict

Sugi Predict / Compounds / SCHEMBL92848

SCHEMBL92848

SCHEMBL92848

NC(=O)CCCC(N)C(=O)NP

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ DPP8 Q6V1X1 6/20 0.43
▸ DPP9 Q86TI2 6/20 0.43
▸ DPP4 P27487 5/20 0.43
▸ DPP7 Q9UHL4 6/20 0.39
▸ SLC15A1 P46059 1/20 0.39
▸ CHRM2 P08172 1/20 0.37
▸ CHRM4 P08173 1/20 0.37
▸ CHRM1 P11229 1/20 0.37
▸ GNAI3 P08754 1/20 0.34
▸ GNAO1 P09471 1/20 0.34
▸ GNAI1 P63096 1/20 0.34
▸ NOS2 P35228 3/20 0.33
▸ NOS1 P29475 3/20 0.33
▸ NOS3 P29474 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ GSR P00390 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL92829 0.89 BLM (0.56) KMT2AALOX15BLMPMP22DPP8
SCHEMBL86359 0.79 DPP8 (0.47) KMT2AALOX15BLMPMP22DPP8
SCHEMBL8209380 0.77 KMT2A (0.54) KMT2AALOX15BLMPMP22DPP8
SCHEMBL9021158 0.77 GRM8 (0.58) KMT2AALOX15BLMPMP22DPP8
SCHEMBL16946430 0.76 CA12 (0.36) KMT2AALOX15BLMPMP22DPP8
SCHEMBL5333534 0.74 — —
SCHEMBL30360155 0.73 CHRM2 (0.43) KMT2AALOX15BLMPMP22DPP8
SCHEMBL9823333 0.73 BLM (0.50) KMT2AALOX15BLMPMP22DPP8
SCHEMBL5328651 0.73 KMT2A (0.77) KMT2AALOX15BLMPMP22NOS2
SCHEMBL3739405 0.73 KMT2A (0.77) KMT2AALOX15BLMPMP22NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120237475-A1 Novel Inhibitors PROBIODRUG AG (DE) 2012-09-20 — — US disclosed
US-8202897-B2 pharmaceutically acceptable salt, solvate or polymorph for disease therapy PROBIODRUG AG (DE) 2012-06-19 — — US disclosed
US-8129160-B2 Method of screening for inhibitors of glutaminyl cyclase activity PROBIODRUG AG (DE) 2012-03-06 — — US disclosed
US-20110092501-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-04-21 — — US disclosed
US-7732162-B2 Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases PROBIODRUG AG (DE) 2010-06-08 — — US disclosed
US-20100125086-A1 USE OF ISOQC INHIBITORS PROBIODRUG AG (DE) 2010-05-20 — — US disclosed
US-20100119475-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2010-05-13 — — US disclosed
US-20100040575-A1 USE OF INHIBITORS OF GLUTAMINYL CYCLASE AND GLUTAMATE CYCLASE FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES PROBIODRUG AG (DE) 2010-02-18 — — US disclosed
US-20100009337-A1 NOVEL GENES RELATED TO GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2010-01-14 — — US disclosed
US-7462599-B2 Use of effectors of glutaminyl and glutamate cyclases PROBIODRUG AG (DE) 2008-12-09 — — US disclosed
US-20080286810-A1 Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders; drug screening PROBIODRUG AG (DE) 2008-11-20 — — US disclosed
US-20080262065-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASES PROBIODRUG AG (DE) 2008-10-23 — — US disclosed
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-08-28 — — US disclosed
US-20080200567-A1 IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS PROBIODRUG AG (DE) 2008-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119475-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, GLUL KMT2A 2609/4885ALOX15 2750/4885BLM 3746/4885
US-20100040575-A1 USE OF INHIBITORS OF GLUTAMINYL CYCLASE AND GLUTAMATE CYCLASE FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES QPCT, GLS, GLUL KMT2A 3450/4885ALOX15 2576/4885BLM 1633/4885
US-20110092501-A1 NOVEL INHIBITORS GLUL, QPCT, GLS KMT2A 2173/4885ALOX15 1892/4885BLM 3535/4885
US-20080200567-A1 IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS QPCT, PCYT1A, PSEN2 KMT2A 1486/4885ALOX15 4475/4885BLM 3103/4885
US-20080262065-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASES GLS, GLS2, GLUL KMT2A 2920/4885ALOX15 1840/4885BLM 3837/4885
US-20120237475-A1 Novel Inhibitors GLS, NQO2, GLS2 KMT2A 3087/4885ALOX15 3221/4885BLM 2464/4885
US-20100125086-A1 USE OF ISOQC INHIBITORS QPCT, QPCTL, GGCT KMT2A 3084/4885ALOX15 1931/4885BLM 2404/4885
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL KMT2A 1852/4885ALOX15 1027/4885BLM 3823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.